|
Thursday, December 12, 2024, 7:15 PM – 9:15 PM CT (8:15 PM – 10:15 PM ET) | San Antonio, Texas
Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast CancerPart 3 of a 3-Part CME Satellite Symposium Series in Partnership with the 2024 San Antonio Breast Cancer Symposium®
Location
San Antonio Marriott Rivercenter 101 Bowie St San Antonio, Texas Hotel Phone: (210) 223-1000 Program Schedule — Central Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 9:15 PM — Educational Dinner Meeting Buffet will open at 7:00 PM CT. Meeting Room Grand Ballroom G-M (Third Floor) This event will also be webcast live. Please see Registration tab for details. Faculty
Erika Hamilton, MD Director, Breast Cancer Research Program Sarah Cannon Research Institute Nashville, Tennessee Kevin Kalinsky, MD, MS Professor Department of Hematology and Medical Oncology Emory University School of Medicine Director, Division of Medical Oncology Director, Glenn Family Breast Center Winship Cancer Institute of Emory University Atlanta, Georgia Ian E Krop, MD, PhD Associate Cancer Center Director for Clinical Research Director, Clinical Trials Office Yale Cancer Center New Haven, Connecticut Joyce O’Shaughnessy, MD Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Chair, Breast Disease Committee Sarah Cannon Research Institute Dallas, Texas Sara M Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc. This is not an official program of the San Antonio Breast Cancer Symposium®.
Program Schedule — Central Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 9:15 PM — Educational Dinner Meeting Buffet will open at 7:00 PM CT. MODULE 1: Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC)
MODULE 2: Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
MODULE 3: Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant HR-Positive mBC
MODULE 4: Tolerability Considerations with the Use of Commonly Employed Therapies
MODULE 5: Other Important Care Considerations for Patients with mBC
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Hamilton — Consulting Agreements (Paid to Institution): Accutar Biotechnology Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Circle Pharma, Daiichi Sankyo Inc, Ellipses Pharma, Entos Pharmaceuticals, Fosun Pharma USA Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Jefferies LLC, Johnson & Johnson Pharmaceuticals, Lilly, Medical Pharma Services SRO, Mersana Therapeutics Inc, Novartis, Olema Oncology, Pfizer Inc, Stemline Therapeutics Inc, Tempus, Theratechnologies, Tubulis, Zentalis Pharmaceuticals; Contracted Research (Paid to Institution): AbbVie Inc, Accutar Biotechnology Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, Akesobio Australia Pty Ltd, Amgen Inc, Aravive Inc, ARS Pharmaceuticals, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, AtlasMedx Inc, BeiGene Ltd, Black Diamond Therapeutics Inc, Bliss Biopharmaceutical (Hangzhou) Co Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Compugen, Context Therapeutics, Cullinan Therapeutics, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Duality Biologics, eFFECTOR Therapeutics Inc, Eisai Inc, Ellipses Pharma, Elucida Oncology Inc, EMD Serono Inc, Fochon Pharmaceuticals, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Inspirna, InventisBio, Jacobio Pharmaceuticals Group Co Ltd, Karyopharm Therapeutics, K-Group Beta, Kind Pharmaceuticals LLC, Leap Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Merus, Myriad Genetic Laboratories Inc, Novartis, NuCana, Olema Oncology, Oncothyreon, ORIC Pharmaceuticals, Orinove Inc, Orum Therapeutics, Pfizer Inc, PharmaMar, Pieris Pharmaceuticals Inc, Pionyr Immunotherapeutics, Plexxikon Inc, Prelude Therapeutics, ProfoundBio, Radius Health Inc, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Repertoire Immune Medicines, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Stemline Therapeutics Inc, Sutro Biopharma, Syndax Pharmaceuticals, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tolmar, Transcenta, Treadwell Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc; Nonrelevant Financial Relationships: Dana-Farber Cancer Institute, Verascity Science. Dr Kalinsky — Advisory Committees: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, Cullinan Therapeutics, Cyclacel Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc, Prelude Therapeutics, RayzeBio, Regor Therapeutics Group, Seagen Inc; Data and Safety Monitoring Board/Committee: Merck; Stock Options/Stock — Public Companies: Grail Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc (spouse prior employment). Dr Krop — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Novartis, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group; Contracted Research: MacroGenics Inc, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Merck, Novartis, Seagen Inc. Dr O'Shaughnessy — Advisory Committees and Consulting Agreements: Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Byondis, Caris Life Sciences, Daiichi Sankyo Inc, DAVA Oncology, Eisai Inc, Exact Sciences Corporation, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Tempus, Veru Inc. Dr Tolaney — Consulting Agreements: Aadi Bioscience, Artios Pharma Limited, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech SE, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Hengrui Therapeutics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Lilly, Menarini Group, Merck, Natera Inc, Novartis, Pfizer Inc, Reveal Genomics, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Sumitovant Biopharma, SystImmune Inc, Tango Therapeutics, Umoja Biopharma, Zentalis Pharmaceuticals, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer Inc, Seagen Inc, Stemline Therapeutics Inc; Travel Support: BioNTech SE, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Lilly, Pfizer Inc, Sanofi. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc. San Antonio Marriott Rivercenter
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in San Antonio, you must also be registered to attend the 2024 San Antonio Breast Cancer Symposium®. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |